Raphael Pharmaceutical (RAPH) Accounts Payables (2020 - 2025)

Raphael Pharmaceutical has disclosed Accounts Payables across 6 years of filings, most recently posting $163000.0 for Q4 2025.

• In Q4 2025, Accounts Payables rose 30.4% year-over-year to $163000.0; the TTM figure through Dec 2025 stood at $163000.0 (up 30.4% YoY), while the FY2025 annual figure was $163000.0, up 30.4% from the prior year.
• Accounts Payables came in at $163000.0 for Q4 2025 at Raphael Pharmaceutical, up from $125000.0 in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $272000.0 in Q4 2021 to a low of $12000.0 in Q3 2021.
• Average Accounts Payables over 5 years is $118833.3, with a median of $98500.0 recorded in 2022.
• Year-over-year, Accounts Payables jumped 2922.22% in 2021 and slumped 73.53% in 2022.
• Over 5 years, Accounts Payables stood at $272000.0 in 2021, then tumbled by 73.53% to $72000.0 in 2022, then dropped by 4.17% to $69000.0 in 2023, then jumped by 81.16% to $125000.0 in 2024, then soared by 30.4% to $163000.0 in 2025.
• Per Business Quant data, the three most recent Accounts Payables figures were $163000.0 in Q4 2025, $125000.0 in Q4 2024, and $69000.0 in Q4 2023.